Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
Stay up to date on the orthopedic market’s 3Q performance in 2023 as we update this post with company sales data and industry developments.
Commercial scale, emerging segments and digital technology are driving growth in some of the market’s best-performing companies.
The company notched its fifth consecutive quarter with more than 20% growth and is on track for arthroscopic MACI delivery in 1H24.
The company grew 61% as-reported in the third quarter of 2023, or 1.2% on a pro forma basis including prior year SeaSpine sales.
The company grew in the mid-teens during the third quarter of 2022, driven by sales force and active surgeon base growth.
The company grew more than 23% in 3Q23 but ultimately reduced its guidance because of higher-than-expected seasonality during the summer.
The company grew in the low single digits in the third quarter of 2023 as its OA pain sales volume offset price declines.
ORTHOWORLD Experts talk you through market forecasts, company sales and key trends.
The company grew in the mid-single-digits in the third quarter of 2023, driven by knee replacement and its SET product category.
The company grew more than 50% in the third quarter of 2023 as it benefit from continued share growth and a month of NuVasive sales.
The company grew more than 40% in the third quarter of 2023 as it procedural solutions continue winning significant market share.
The company grew nearly 29% in the third quarter of 2023, notching its sixth consecutive quarter of record revenues.
The company grew in the high-single-digits in the third quarter of 2023, driven by market recovery and improving operational performance.
The company grew in the mid-single-digits for the third quarter of 2023, driven by new products and better-than-expected orthobiologics sales.
The company grew in the high-single-digits in the third quarter of 2023, driven by new products and robotic procedures.
The company’s 3Q23 orthopedic sales declined by nearly 10% due to continued competitive pressure and an exit from the Chinese market.
X-Bolt Orthopaedics raised $3.5 million and seeks to raise up to $1 million more before the end of the year as it seeks to scale in the U.S.
CONMED reported 3Q23 orthopedic sales of $124.7 million, +5.1% compared to the third quarter of 2022. For the first nine…
Don't have an account? Register
Forgot your password? Reset
Register for a free account
As a guest member you get access to more articles and webinars every month.
We noticed you used your personal email account. Please enter your company website URL.
Already have an account? Login
We’ll send a recovery link to your email.
I already have an account! Login